As per data available with the stock exchanges, Handa sold 11,80,120 shares amounting to 1.85% stake in Claris Lifescience through open market transaction.
The shares were bought on an average price of about Rs 200 valuing the transaction to Rs 23.60 crore.
Also Read
In August last year, Handa had sold 10 lakh shares of the company for an estimated Rs 16.20 crore, while in July he had offloaded 17.33 lakh shares for Rs 28 crore.
At the of January-March quarter, Handa held 33.71 lakh shares or 5.28% stake in Claris Lifesciences, while Caduceus Capital Master Mauritius Ltd held 7.50 lakh scrips or 1.18% holding in the drug firm.
Claris Lifesciences scrip fell 3.32% to settle at Rs 190.75 apiece on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)